Announcements

As a leader in open access publishing, MDPI is eager to explore new collaboration opportunities, including the launch of new journals and the transfer of existing ones. At present, MDPI publishes over 400 journals, more than 160 of which have established partnerships with academic organizations. Additionally, we publish 19 association journals.

In order to enhance exchange and cooperation with scientific researchers and share the results of open science, MDPI invites experts and scholars from various fields to submit proposals for new journal collaboration opportunities. If your proposal is approved, you could take on the role of Editor-in-Chief, Deputy Editor-in-Chief, or Editorial Board Member of the journal. This position allows you to manage the manuscript review process alongside our editorial department, participate in calls for papers, strengthen your network with scholars in the field, expand scientific research cooperation, enhance your personal and academic influence internationally, and play a leading role in academia.

Once the new journal is online, MDPI will provide a variety of promotional channels to market the journal internationally.

MDPI will offer various promotional channels to enhance its visibility and promote it internationally.

How can you determine the theme of a new journal?

• Assess research hotspots/academic frontiers;
• Assess pioneers in the field/key research directions of universities;
• Determine whether MDPI has already established a journal in the field.

You can browse MDPI’s existing journals at the following link: https://www.mdpi.com/about/journals.

Advantages of collaborating with MDPI:

• MDPI is a global leader in open-access publishing with extensive academic resources.
• MDPI offers a professional publishing team that provides comprehensive support throughout the publishing process.
• MDPI’s diverse promotional platforms and channels help journals quickly increase their international visibility and influence.

We invite you to submit new journal proposal here, and contribute to academic development! In addition, if your institution (university, institute, college, national key laboratory, society, etc.) intends to establish a journal, you can also submit a draft to MDPI on its behalf.

MDPI journals frequently grant travel awards to empower junior researchers to showcase their latest research at academic conferences, thereby amplifying their impact within their research fields.

We extend our heartfelt congratulations to the 103 recipients of MDPI's 2023 Travel Awards from different countries and territories for their exceptional presentations. These outstanding individuals were selected by the journal editors based on the strength of their research proposals and the anticipated impact of their presentations at academic conferences. We commend their exceptional contributions and wish them continued success in their academic endeavors.

MDPI will continue to provide support and recognition to the academic community. To learn more about the list of awardees, please visit the following pages:

• Biology and Life Sciences;
• Chemistry and Materials Sciences;
• Engineering;
• Environmental and Earth Sciences;
• Medicine and Pharmacology;
• Public Health and Healthcare;
• Others.

About MDPI Awards:

To reward the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help raise the influence of talented individuals who have been credited with outstanding achievements and are making a significant contribution to the advancement of their fields.

To explore more MDPI awards, please click here.

We are pleased to announce that the Journal of Pharmaceutical and BioTech Industry (JPBI, ISSN: 2813-9380) has established a companionship with its sister journal, Pharmaceutics (ISSN: 1999-4923).

The Journal of Pharmaceutical and BioTech Industry is an international, peer-reviewed, and open access journal committed to publishing research and development studies on all aspects of science, engineering, and technology applicable to the pharmaceutical and biotech industry sectors, published quarterly online by MDPI. The founding Editor-in-Chief is Prof. Dr. Ecevit Bilgili from the New Jersey Institute of Technology, USA.

The Journal of Pharmaceutical and BioTech Industry aims to create a platform on which scientists and engineers from academia, industry, and regulatory as well as other governmental agencies share and complement each other’s discoveries and advance science, engineering, and technology with the goal of enhancing patient wellbeing. All aspects of the discovery, development, delivery, and manufacturing of drugs (drug substances and drug products, including biodrugs, delivery devices, diagnostic agents, etc.) are covered. We accept original research articles, critical and timely reviews, short communications, opinions, technical notes, reports, and expert perspectives. For details on the background and scope of this journal, please click on the following link: https://www.mdpi.com/journal/jpbi/about.

We offer a full waiver on article processing charges for papers submitted before 1 January 2025. Manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 5.8 days (median values for MDPI journals in the first half of 2024). If accepted after peer review, your paper will be published in an open access format.

Manuscripts can be submitted via the journal’s online submission system at the following link: https://susy.mdpi.com/user/manuscripts/upload?journal=jpbi.

You can read the Opening Editorial by the Editor-in-Chief at the following link: https://www.mdpi.com/2813-9380/1/1/3.

You can read the short interview with Prof. Dr. Ecevit Bilgili, the Editor-in-Chief, who shared his vision for the journal with us, as well as his views of the area and open access publishing: https://www.mdpi.com/journal/jpbi/announcements/9313.

We cordially invite you to consider the Journal of Pharmaceutical and BioTech Industry as the platform for publishing your work.

JPBI Editorial Office

MDPI’s Best PhD Thesis Awards are granted to promising young scholars whose PhD theses are deemed exceptional within their respective research fields. These awards aim to encourage young scholars to continue their outstanding accomplishments and further contribute to their field.

We extend our heartfelt congratulations to the 54 winners of the 2023 Best PhD Thesis Awards and wish them success with their future research endeavors.

MDPI will continue to provide support and recognition to the academic community. To learn more about all the awardees and their research projects in your field of study, please visit the following pages:

About MDPI Awards:

To reward the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help raise the influence of talented individuals who have been credited with outstanding achievements and are making a significant contribution to the advancement of their fields.

To explore more MDPI awards, please click here.

We are pleased to announce that Prof. Dr. Ecevit Bilgili has been appointed as the Founding Editor-in-Chief of Journal of Pharmaceutical and BioTech Industry (JPBI, ISSN: 2813-9380).

Homepage: https://chemicaleng.njit.edu/people/bilgili.php
Affiliation: Otto H. York Department of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA
Interests: particle engineering; pharmaceutical nanotechnology; drug nanosuspensions and nanocomposites; amorphous solid dispersions; multi-scale process modeling; pharmaceutical unit operations; milling; granulation; spray drying; extrusion

Prof. Dr. Ecevit Bilgili is a professor, master teacher, and associate chair of the Chemical and Materials Engineering department at the New Jersey Institute of Technology (NJIT), USA. His Particle Engineering and Pharmaceutical Nanotechnology Laboratory conducts research in designing formulations and processes for high-value-added products like pharmaceuticals with enhanced functionalities. Before joining NJIT, he worked at Merck and Co., Inc. as a senior principal development engineer and played an instrumental role in the formulation and process development of Janumet® and other drugs in the pipeline. Prof. Dr. Bilgili served as an elected Executive Committee Member of the Particle Technology Forum of AIChE. He also served as the Chair and Vice Chair of AIChE Area3a: Particle Production and Characterization. He authored 110+ peer-reviewed journal articles, 6 U.S. patents, several invention disclosures, and has delivered 120+ national/international conference presentations and 40+ invited talks. Prof. Dr. Bilgili currently serves as an Associate Executive Editor of Advanced Powder Technology, an Editorial Advisory Board member of Pharmaceutical Research, and an Editorial Board Member of Pharmaceutics and Powders journals. He is the recipient of numerous Excellence in Teaching Awards from NJIT and the George Klinzing Best Ph.D. Thesis in Particle Technology Award from the AICHE. Prof. Dr. Bilgili was elected to the AIChE fellowship in 2022. He is in Stanford University’s list of “the top 2% of the most-cited scientists”.

The following is a short Q&A with Prof. Dr. Ecevit Bilgili, who shared his vision for the journal with us, as well as his views of the area and open access publishing:

1. What appealed to you about the journal that made you want to take the role of its Editor-in-Chief?
During my five-year work at Merck and Co., Inc., I was excited about and fascinated with the complexity and multi- and inter-disciplinary nature of R&D, fast pace of the drug development, and tremendous value that pharmaceutical industry provides to health care. After joining academia, I have continued my interactions with several pharmaceutical companies via joint research and development projects. Having served on both sides of the big pharmaceutical enterprise, this gives me a unique perspective about pharmaceutical R&D. My experience shows that great research and development is being conducted at pharmaceutical companies and universities, and I wanted to serve a journal that is tailored to the needs of the pharmaceutical and biotech industry sectors while fostering communications and interactions among all three branches of the pharmaceutical enterprise: academia, industry, and regulatory/other governmental agencies and laboratories. Also, being a Founding Editor-in-Chief, I will have a chance to implement my vision.

2. What is your vision for the journal?
I want to see Journal of Pharmaceutical and BioTech Industry become a leading platform in which scientists and engineers from academia, industry, regulatory, and other governmental agencies share and complement each other’s discoveries and advance science, engineering, and technology with the goal of enhancing patient well-being. The journal’s Editorial Board should and will reflect the diversity in several aspects: technical expertise required for a multitude of sciences and engineering disciplines involved in R&D and manufacturing, gender, race, and geographic location. As a stark contrast to our sister MDPI journals Pharmaceutics and Pharmaceuticals, Journal of Pharmaceutical and BioTech Industry will have many Editorial Board Members who are scientists and engineers from industry and regulatory agencies. Hence, I want to grow the journal with diverse constituencies’ involvement. In collaboration with the Editorial Board, we will also diversify the types of papers published, not just original research articles and reviews. I would like to see a growing number of perspectives, opinions, and various types of reports such as position papers, especially those written by academic experts and industry regulatory experts and leaders. In addition, we will strive to publish selected papers from various conferences. Finally, we will emphasize Special Issues in emerging fields pertaining to the discovery, development, delivery, and manufacturing of drugs. 

3. What does the future of this field of research look like?
Well, this is a great question whose answer cannot be concisely given in a short interview because the pharmaceutical research field is huge and diverse, considering all aspects of the discovery, development, delivery, and manufacturing of drugs. Exciting developments are happening in all these areas. I will just pick a few examples that are illustrative and have the widest impact. Perhaps, one huge development is in the field of modeling as applied to all the above areas. Fueled by the advances in computational power (hardware, software, algorithms, and numerical methods) as well as by the widespread use of AI-ML tools, any system (pharmaceutical phenomena, drug chemistry and interactions, equipment, process, formulation, etc.) can be simulated in silico and literal “digital twins” can be developed. The ever-increasing use of modeling and digital twins will have a revolutionary impact on pharmaceutical and biotech industries. Similarly, personalized medicine approaches and additive manufacturing–3D printing, in an integrated fashion, may revolutionize how medicines are supplied to patients. Finally, while providing safe and efficacious medicines, in an effort to enhance affordability and accessibility globally, pharmaceutical and biotech companies will continue to reduce costs including those of R&D and manufacturing, partly due to ever-increasing pressure from payors and public. From an R&D and manufacturing perspective, this will require the development/adaption, integration, or adoption of existing or emerging chemical engineering approaches such as model-aided process design, process control, process optimization and intensification, and continuous manufacturing processes. I am confident that in the near future, drug product manufacturing will become more advanced than the manufacturing of household products. The pharmaceutical enterprise has already moved in this direction, and the best is yet to come.

4. What do you think of the development of open access in the publishing field?
Open access has enabled wide accessibility and fast dissemination of knowledge in all branches of science and engineering, which is a positive and favorable development. In fact, recognizing the value of open access, most print journals have moved to a hybrid modality with open access options. Personally, two out of my five most cited papers appeared in Pharmaceutics, an open access MDPI journal. The Creative Commons Attribution (CC BY) license allows authors utmost flexibility to share, copy, redistribute, and adapt their materials. Some print journals impose severe limitations on authors as to how they can share, reuse, and adapt their published materials, which is quite unfavorable to the authors. Hence, as a scientist, I support open access publishing wholeheartedly. Moreover, MDPI is a pioneer in scholarly, open access publishing. I really appreciate that MDPI offers various discounts to individual researchers and institutions, vouchers to reviewers, etc., that will help more researchers, especially those in underdeveloped countries, to participate in open access publishing.

We warmly welcome Prof. Dr. Ecevit Bilgili and wish him every success in the position. Further details regarding the founding Editorial Board of Journal of Pharmaceutical and BioTech Industry can be found at the following link: https://www.mdpi.com/journal/jpbi/editors.

MDPI’s Young Investigator Awards recognize promising early career scientists, acknowledge their contributions, and foster collaboration within the scientific community. We are proud to announce the recipients for 2023, who were carefully selected by the journals’ esteemed Award Evaluation Committee.

We extend our heartfelt congratulations to the 79 winners of MDPI’s 2023 Young Investigator Awards for their excellent contributions in their research field. We look forward to seeing these rising stars continue to contribute to the advancement of science.

MDPI will continue to support and recognize the academic community. To explore details about the awardees by field, please visit the individual pages listed below:

Congratulations to all the winners for their exceptional contributions and dedication to advancing scientific research.

About MDPI Awards:
To support the academic community, particularly young researchers, and to enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help to elevate the profiles of talented individuals who have made outstanding achievements and are making significant contributions to advancements in their respective fields.

To find out more about MDPI awards, please click here.

In May, MDPI Romania held three author training sessions – one endorsing an external event and two stand-alone sessions.

The National Session of Scientific Student Communications took place at Technical University Cluj on 17 and 18 May 2024. MDPI Romania sponsored this event and contributed an author training session on the production of research papers and case study analyses. JRS Norbert Kiss gave a presentation called The World of Open Access to explain different open access publishing models and the benefits of open access publishing. His presentation highlighted the impact of open access publishing on scientific progress and innovation.

On 29 May 2024, MDPI Romania hosted an author training session for Ph.D. students, early career researchers, and professors at the Carol Davila University of Medicine and Pharmacy. In collaboration with Prof. Andreea Arsene, JRS Ioana Paunescu prepared two presentations: The Steps of the Publishing Process and Elaboration of a Peer Review Report. In her first presentation, she delved into MDPI’s history and mission, MDPI’s editorial process, and MDPI journals of various scopes that are accepting submissions. Her second presentation outlined the types of peer review, the contents of a peer review report by an MDPI reviewer, and the responsibilities of an MDPI reviewer.

MDPI Romania also hosted an author training session at the Iasi University of Life Sciences on 29 May 2024. JRSs Laurentiu Preda and Cosmin Artan gave four presentations: Efficient Writing of an ISI-Indexed Scientific Article, Benefits of Publishing in the Open Access Model, Various Methods of Open Access Publishing, and MDPI Guide for the Article Review Process. The first three presentations offered guidance on how to improve academic writing, the fourth focused on how to write peer review reports. A highly interactive discussion followed the presentations, during which the JRSs provided extensive answers to attendees’ questions.

MDPI is grateful for all the attendees, speakers, and organizers involved in these events. Through their enthusiasm and dedication, these events were great successes.

Five new journals covering multiple subjects have launched their inaugural issue in June 2024. We are excited to be able to share with you the newest research rooted in the value of open access.

We would like to express our deepest appreciation to all the Editorial Board Members and each journal will ensure its high-quality output using excellent editorial and rigorous peer review processes, to ensure that the articles achieve high impact and visibility.

Please feel free to browse and discover more about the new journals below.

Journal	Founding Editor-in-Chief	Journal Topics (Selected)
	Prof. Dr. Marco Ranucci, IRCCS Policlinico San Donato, Italy | Editorial | view inaugural issue	anaesthetic medications; blood and fluid management; pain management; critical care; critical illness | view journal scope | submit an article
	Dr. Giovanni E. Cacciamani, University of Southern California, USA | Editorial | view inaugural issue	surgical/procedural complications; complications; perioperative adverse events; postoperative adverse events | view journal scope | submit an article
	Prof. Dr.  Gassan Hodaifa, Universidad Pablo de Olavide, Spain | Editorial | view inaugural issue	laboratory management; laboratory safety; protective equipment; laboratory problems and challenges; laboratory Innovation | view journal scope | submit an article
	Prof. Dr. Jan S. Suchodolski, Texas A&M University, USA | Editorial | view inaugural issue	companion animals health and disease; veterinary care and nutrition; genetics and genomics; behavior and welfare; human-animal relations | view journal scope | submit an article
	Prof. Dr. Pierfrancesco De Paola, University of Naples Federico II, Italy | Editorial | view inaugural issue	real estate appraisal; economic and financial valuation of real estate projects; sustainable real estate; housing and urban economics | view journal scope | submit an article

We wish to thank everyone who has supported the development of open access publishing. You are welcome to send an application here, or contact the New Journal Committee ([email protected]) if you would like to create more new journals.